Hospitals
Medical Offices/Clinics
Interactive Map
Physician Publications
Dr. Sara Hurvitz is a medical oncologist who practices in the Santa Monica Parkside office, which houses UCLA Health’s integrative breast cancer practice and high-risk breast cancer clinic. She specializes in the treatment of women with breast cancer, and is involved in designing, implementing and leading national and international clinical trials to test new targeted therapies. She is board certified in internal medicine and medical oncology.
Dr. Hurvitz maintains a robust clinical and translational research portfolio, for which she has won numerous awards over the years, including the Marni Levine Memorial Breast Cancer Research Award in years between 2008 and 2015. She currently leads the Translation Oncology Research Laboratory at UCLA in the preclinical evaluation of novel breast cancer targets.
Dr. Hurvitz earned her medical degree from the University of Southern California School of Medicine. She then completed her internal medicine residency at UCLA, serving as chief resident, followed by her hematology/oncology fellowship at UCLA.
Dr. Hurvitz is an associate professor at the David Geffen School of Medicine at UCLA; medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit; co-director of the Santa Monica-UCLA Outpatient Oncology Practices; and director of the Breast Cancer Clinical Trials Program at UCLA. She is also a member of the American Society of Clinical Oncology and the American Association of Cancer Research, and is a fellow of the American College of Physicians.
Dr. Sara Hurvitz is interested in designing and implementing phase I and II (translational) breast cancer clinical trials. She is particularly interested in the development and testing of new targeted therapies for the treatment of breast cancer.
Dr. Hurvitz is also interested in studying the gene expression patterns in a variety of breast cancer populations, and evaluating these patterns to detect new subtypes of breast cancer that may be more accurately targeted by novel therapies.
